Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges
about
Contemporary and emerging strategies for eliminating human African trypanosomiasis due to Trypanosoma brucei gambiense: reviewCan Economic Analysis Contribute to Disease Elimination and Eradication? A Systematic ReviewControl, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in AfricaFinancial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in AfricaWhat Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration ProgramsFrom Haiti to the Amazon: public health issues related to the recent immigration of Haitians to Brazil.Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.Evaluating the sustainability, scalability, and replicability of an STH transmission interruption intervention: The DeWorm3 implementation science protocol.Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas diseasInvesting in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasisEthical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for
P2860
Q26825682-5DF48A48-AC9A-48E5-AC53-EDDC23A5C0E3Q27012936-F871A201-A73C-4884-B098-FF3493775A08Q28546065-CDB866BF-9808-44EC-B42E-183588D4965CQ28547910-16778F70-AD10-4E42-8C83-8494FBA6674BQ28550175-042F52D8-DB90-4A2B-8427-88654E8D3CB1Q31160732-CB2E22DA-C670-44A2-A89C-29A5E37DA102Q37659611-9DA4EFE8-28B6-4D4C-B978-07689291DD2FQ41994054-4441DB10-42B7-4674-9CB3-9150C157013FQ47725422-39CD6C3B-EB94-4079-9539-BC32C3314987Q51740777-BF1EEB25-FDDE-413B-AF68-BC448D7DE071Q56835282-4B29A4AF-F027-47F1-97DF-2A729E35B034Q58842233-2A3C5F92-DDAF-4987-89AF-455F9535A0DA
P2860
Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Developing eradication investm ...... rationale and main challenges
@en
Developing eradication investm ...... rationale and main challenges.
@nl
type
label
Developing eradication investm ...... rationale and main challenges
@en
Developing eradication investm ...... rationale and main challenges.
@nl
prefLabel
Developing eradication investm ...... rationale and main challenges
@en
Developing eradication investm ...... rationale and main challenges.
@nl
P2860
P50
P921
P1476
Developing eradication investm ...... rationale and main challenges
@en
P2093
Peter Steinmann
P2860
P356
10.1371/JOURNAL.PNTD.0002446
P407
P577
2013-11-07T00:00:00Z